Venture Capital Firms Investing in Quantum Chemicals and in Quantum Life Science
IQT Quantum Chemical & Quantum Life Science August 5-12, 2026
In this week’s edition, IQT details what VC firms are making investments in 1) Quantum Chemistry and 2) Quantum Life Science.
The venture capital landscape for quantum chemistry and quantum life sciences has experienced heavy acceleration throughout 2025 and 2026. Total venture capital flows into quantum tech reached a record $4.9 billion in 2025, with the market shifting toward strategic mid-range rounds, sovereign support, and specialized software stacks in 2026. [1, 2]
In May 2026, the U.S. Government shifted the funding landscape by deploying $2 billion in grant funding through the CHIPS and Science Act specifically for quantum hardware infrastructure. In exchange for equity, this capital is directly building out the physical infrastructure that quantum chemistry and life science software companies rely on: [1, 2, 3]
Additionally, Denmark’s export fund teamed up with Novo Holdings to launch the €134M 55 North Fund, explicitly tasked with pumping early-stage VC into healthcare-focused quantum ventures. [1]
Venture capital firms backing quantum chemistry and quantum life sciences are split between dedicated quantum funds, deep-tech generalists, and life science giants. [1, 2]
Computational chemistry and molecular biology both require massive, high-risk capital. This long research duration is often termed the “valley of death”. VCs invest here because simulating molecular structures can revolutionize chemical engineering and therapeutics. [1]
I. Quantum Chemistry Investors
Venture capital in quantum chemistry targets materials discovery, catalyst design, and molecular simulation. [1, 2, 3, 4] Leading firms are:
- Quantonation: Pioneering specialist fund managing over €220M. They target physics-based innovations. They back molecular simulation platforms globally. [1, 2, 3]
- DCVC (Data Collective): Deep-tech VC managing multiple billions. They heavily prioritize “picks-and-shovels” computational infrastructure. They fund quantum platforms solving chemical engineering bottlenecks. [1, 2, 3]
- Lux Capital: Manages a $1.5B Fund IX. They specialize in contrarian, hard science infrastructure. Their thesis supports long commercialization timelines in materials discovery. [1, 2, 3]
- Andreessen Horowitz (a16z): Invests via its infrastructure funds. They look for advanced software platforms capable of industrial-grade chemical modeling. [1, 2]
- Andreessen Horowitz (a16z): Invests via its infrastructure funds. They look for advanced software platforms capable of industrial-grade chemical modeling. [1, 2]
- NVentures (NVIDIA): Corporate venture arm investing heavily in hybrid systems. They focus on GPU-accelerated quantum simulation for chemical modeling.
II. Quantum Chemistry Funding Rounds
Funding in this sector focuses heavily on advanced materials simulation, quantum software platforms, and hybrid GPU-quantum acceleration. Leading rounds as of this publication are:
- Quantum Motion ($160M Series C — May 2026)
- Focus: Silicon transistor-based fault-tolerant quantum computing.
- Significance: Its scalable silicon architecture is optimized to run dense molecular and materials simulations at a fraction of the cost of other systems.
- Key Investors: Co-led by DCVC and Kembara. [1]
- QuantWare ($178M Series B — May 2026)
- Focus: Massive open-architecture quantum foundry.
- Significance: Builds hardware configurations tailored for commercial physics and chemistry modeling software.
- Key Investors: Undisclosed deep-tech consortiums and European growth funds. [1]
- Casimir ($12M Seed — May 2026)
- Focus: Quantum energy semiconductor chips.
- Significance: Explores real-world quantum vacuum fields for energy applications, anchoring a major sub-sector of quantum material sciences.
- Key Investors: Led by Scout Ventures, with participation from Lavrock Ventures, Cottonwood Technology, and Draper Associates. [1]
III. Quantum Life Science Investors
Venture capital in quantum life sciences targets quantum biology, drug discovery pipelines, and clinical diagnostics. [1, 2]
- Novo Holdings: A leading global life sciences investor. They anchored the €134M quantum-tech fund 55 North. They also invest directly into algorithm startups like Phasecraft. Their explicit goal is steering quantum applications into biotech. [1, 2, 3]
- Qubits Ventures: A specialist early-stage firm. They actively build ecosystems bridging quantum mechanics and life sciences. They focus on enzyme catalysis and quantum sensing for medicine. [1, 2]
- a16z Bio + Health: A dedicated branch of Andreessen Horowitz. They target the intersection of biology and advanced computation. They view “biology as technology”. [1, 2, 3, 4]
- Khosla Ventures: Prominent deep-tech and medicine fund. They specialize in long-horizon, high-risk research. They actively back early quantum platforms capable of complex biological replication. [1, 2]
- Google Ventures (GV): Backs early deep-tech infrastructure. They specifically focus on AI-quantum convergence for therapeutic discovery. [1, 2, 3]
IV: Quantum Life Science Funding Rounds:
Funding here targets the “AI-Quantum convergence,” translating quantum algorithms directly into structural biology, enzyme optimization, and pharmaceutical design.
- XtalPi ($268M Post-IPO Placement — February 2025)
- Focus: Quantum physics and AI-driven drug discovery.
- Significance: Serves as a primary cross-over player using quantum chemistry algorithms to automate biological target identification.
- Key Investors: SoftBank Vision Fund, Tencent, and OrbiMed. [1]
- Phasecraft ($34M Series B — September 2025)
- Focus: Quantum algorithms for real-world modeling.
- Significance: This is a landmark deal for life sciences. Phasecraft writes algorithms that compress the number of qubits needed to simulate complex chemical and biological reactions.
- Key Investors: Co-led by Plural, Playground Global, and notably, Novo Holdings’ Quantum Fund (marking their first-ever direct investment into quantum software). [1, 2, 3]
- Liangzhi Kaiwu (Angel & Series A — Mid 2026)
- Focus: Quantum-AI software for diagnostic and clinical applications.
- Significance: A joint venture specializing in combining quantum measurement control systems with biometric analysis tools.
- Key Investors: Co-led by Beijing Information Industry Development Investment Fund and Shunwei Capital. [1]
